Immunotherapy for HER2-positive breast cancer: recent advances and combination therapeutic approaches
Nehad M Ayoub,1 Kamal M Al-Shami,2 Rami J Yaghan3 1Department of Clinical Pharmacy, Faculty of Pharmacy, Jordan University of Science and Technology (JUST), Irbid, Jordan; 2Department of Drug Discovery and Development, Harrison School of Pharmacy, Auburn University, Auburn, AL, USA; 3Department of G...
Guardado en:
Autores principales: | Ayoub NM, Al-Shami KM, Yaghan RJ |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2019
|
Materias: | |
Acceso en línea: | https://doaj.org/article/5fb05676bd394ccdbb48619e7081b012 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Cancer Vaccines and Immunotherapy for Tumor Prevention and Treatment
por: Jagmohan Singh, et al.
Publicado: (2021) -
Editorial: Immunotherapy as an Evolving Approach for the Treatment of Breast Cancer
por: Mai F. Tolba, et al.
Publicado: (2021) -
Early Antibiotic Exposure Is Not Detrimental to Therapeutic Effect from Immunotherapy in Hepatocellular Carcinoma
por: Petros Fessas, et al.
Publicado: (2021) -
Recent advances of cyclin-dependent kinases as potential therapeutic targets in HR+/HER2− metastatic breast cancer: a focus on ribociclib
por: Edessa D, et al.
Publicado: (2017) -
Place of CDK 4/6 and PARP inhibitors in the modern treatment approach of HER2-negative breast cancer
por: Board Editorial
Publicado: (2021)